Pulmatrix (PULM) Competitors $5.35 -0.28 (-4.97%) As of 08/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PULM vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Pulmatrix stock or one of its competitors? The main competitors of Pulmatrix include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Pulmatrix vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Aravive Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Pulmatrix (NASDAQ:PULM) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk. Is PULM or ATNFW more profitable? 180 Life Sciences has a net margin of 0.00% compared to Pulmatrix's net margin of -122.46%. 180 Life Sciences' return on equity of 0.00% beat Pulmatrix's return on equity.Company Net Margins Return on Equity Return on Assets Pulmatrix-122.46% -94.97% -84.57% 180 Life Sciences N/A N/A N/A Does the media favor PULM or ATNFW? In the previous week, 180 Life Sciences had 1 more articles in the media than Pulmatrix. MarketBeat recorded 2 mentions for 180 Life Sciences and 1 mentions for Pulmatrix. 180 Life Sciences' average media sentiment score of 0.48 beat Pulmatrix's score of -1.00 indicating that 180 Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Pulmatrix Negative 180 Life Sciences Neutral Which has stronger earnings & valuation, PULM or ATNFW? 180 Life Sciences has lower revenue, but higher earnings than Pulmatrix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulmatrix$7.81MN/A-$6.94M-$3.34-1.60180 Life SciencesN/AN/AN/AN/AN/A Do institutionals & insiders hold more shares of PULM or ATNFW? 11.8% of Pulmatrix shares are held by institutional investors. 0.6% of Pulmatrix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Summary180 Life Sciences beats Pulmatrix on 5 of the 8 factors compared between the two stocks. Get Pulmatrix News Delivered to You Automatically Sign up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PULM vs. The Competition Export to ExcelMetricPulmatrixMED IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$2.99B$5.48B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.6017.7428.8623.83Price / SalesN/A178.75371.7266.14Price / CashN/A41.9535.4557.96Price / Book2.188.508.275.54Net Income-$6.94M-$55.06M$3.25B$259.28M7 Day Performance-5.16%-3.99%-3.73%-4.68%1 Month Performance-23.86%9.58%4.29%4.36%1 Year Performance129.74%6.70%25.87%17.89% Pulmatrix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PULMPulmatrix0.1128 of 5 stars$5.33-5.3%N/A+126.8%$0.00$7.81M-1.6020Negative NewsShort Interest ↑Gap DownATNFW180 Life SciencesN/A$0.01-14.0%N/A+18.6%$0.00N/A0.007News CoveragePositive NewsGap DownHigh Trading VolumeLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.13-5.5%N/AN/A$0.00$106.21K0.0040Positive NewsGap DownALVOWAlvotechN/A$1.94-27.1%N/A-47.5%$0.00$585.60M0.004Positive NewsGap UpARAVAraviveN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05-0.6%N/A-35.3%$0.00N/A0.0015High Trading VolumeBFRIWBiofronteraN/A$0.19-5.0%N/A+400.0%$0.00$38.00M0.0070BTMDWbioteN/A$0.01-14.7%N/A-97.2%$0.00$199.38M0.00N/AGap UpBCTXWBriaCell TherapeuticsN/A$0.05+11.4%N/A-82.0%$0.00N/A0.008Short Interest ↑Gap Down Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Aravive Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PULM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
